REVIEW PAPER
Fatigue and interleukin-6 – a multi-faceted relationship
Submission date: 2015-05-20
Final revision date: 2015-07-15
Acceptance date: 2015-08-17
Online publication date: 2015-09-21
Publication date: 2015-09-15
Reumatologia 2015;53(4):207-212
KEYWORDS
TOPICS
ABSTRACT
Many connective tissue diseases are characterized by fatigue, which is described in the literature as prostration, weakness, lassitude or asthenia. In many other diseases (autoimmune, neurologic or metabolic) fatigue impinges on daily activities and thus influences the quality of life. Different molecular backgrounds are involved in the development of fatigue. Not only does the immunosuppressive treatment of autoimmune diseases reduce fatigue, but also selective nutritional components may have an effect on secretion of cytokines which are responsible for development of the sensation of tiredness (e.g. secretion of interleukin-6). The beneficial influence of selected food components (such as polyunsaturated omega-3 fatty acids, nutritional antioxidants or adequate fat intake with the diet) on proinflammatory cytokine secretion has been demonstrated in many studies. In this review, the biochemical, neurological and nutritional aspects of fatigue in autoimmune diseases are underlined.
REFERENCES (51)
1.
Maes M, Mihaylova I, Kubera M, Ringel K. Activation of cell-mediated immunity in depression: association with inflammation, melancholia, clinical staging and the fatigue and somatic symptom cluster of depression Prog Neuropsychopharmacol Biol Psychiatry 2012; 36: 169-175.
2.
Franc M, Michalski B, Kuczerawy I, et al. Cancer related fatigue syndrome in neoplastic diseases. Prz Menopauzalny 2014; 13: 352-355.
3.
van Loo HM, de Jonge P, Romeijn JW, et al. Data-driven subtypes of major depressive disorder: a systematic review. BMC Med 2010; 10: 156.
4.
Fiocco U, Oliviero F, Sfriso P, et al. Synovial biomarkers in psoriatic arthritis. J Rheumatol Suppl 2012; 89: 61-64.
5.
Bonifati C, Carducci M, Cordiali Fei P, et al. Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients – relationships with disease severity. Clin Exp Dermatol 1994; 19: 383-387.
6.
Fragiadaki K, Tektonidou MG, Konsta M, et al. Sleep disturbances and interleukin 6 receptor inhibition in rheumatoid arthritis. J Rheumatol 2012; 39: 60-62.
7.
Leonard B, Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 2012; 36: 764-785.
8.
Neu D, Mairesse O, Hoffmann G, et al. Do ‘sleepy’ and ‘tired’ go together? Rasch analysis of the relationships between sleepiness, fatigue and nonrestorative sleep complaints in a nonclinical population sample. Neuroepidemiology 2010; 35: 1-11.
9.
Patel SR, Zhu X, Storfer-Isser A, et al. Sleep duration and biomarkers of inflammation. Sleep 2009; 32: 200-204.
10.
Vgontzas AN, Papanicolaou DA, Bixler EO, et al. Circadian interleukin-6 secretion and quantity and depth of sleep. J Clin Endocrinol Metab 1999; 84: 2603-2607.
11.
Hogan D, Morrow JD, Smith EM, Opp MR. Interleukin-6 alters sleep of rats. J Neuroimmunol 2003; 137: 59-66.
12.
Vgontzas AN, Zoumakis E, Bixler EO, et al. Adverse effects of modest sleep restriction on sleepiness, performance, and inflammatory cytokines. J Clin Endocrinol Metab 2004; 89: 2119-2126.
13.
Crofford LJ, Kalogeras KT, Mastorakos G, et al. Circadian relationships between interleukin [IL]-6 and hypothalamic-pituitary-adrenal axis hormones: failure of IL-6 to cause sustained hypercortisolism in patients with early untreated rheumatoid arthritis. J Clin Endocrinol Metab 1997; 82: 1279-1283.
14.
Anderson G, Kubera M, Duda W, et al. Increased IL-6 trans-signaling in depression: focus on the tryptophan catabolite pathway, melatonin and neuroprogression. Pharmacol Rep 2013; 65: 1647-1654.
15.
Scheller J, Ohnesorge N, Rose-John S. Interleukin-6 trans-signalling in chronic inflammation and cancer Scand J Immunol 2006; 63: 321-329.
16.
Burmester GR, Feist E, Kellner H, et al. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA0). Ann Rheum Dis 2011; 70: 755-759.
17.
Radovits BJ, Fransen J, Al Shamma S, et al. Excess mortality emerges after 10 years in an inception cohort of early rheumatoid arthritis. Arthritis Care Res 2010; 62: 362-370.
18.
Bradham WS, Ormseth MJ, Oeser A, et al. Insulin resistance is associated with increased concentrations of NT-proBNP in rheumatoid arthritis: IL-6 as a potential mediator. Inflammation 2014; 37: 801-808.
19.
Wolf J, Rose-John S, Garbers C. Interleukin-6 and its receptors: a highly regulated and dynamic system. Cytokine 2014; 70: 11-20.
20.
Theoharides TC, Donelan JM, Papadopoulou N, et al. Mast cells as targets of corticotropin-releasing factor and related peptides. Trends Pharmacol Sci 2004; 25: 563-568.
21.
St John AL, Abraham SN. Innate immunity and its regulation by mast cells. J Immunol 2013; 190: 4458-4463.
22.
Paus R, Theoharides TC, Arck PC. Neuroimmunoendocrine circuitry of the ‘brain-skin connection’. Trends Immunol 2006; 27: 329.
23.
Maachi M, Piéroni L, Bruckert E, et al. Systemic low-grade inflammation is related to both circulating and adipose tissue TNF-αlpha, leptin and IL-6 levels in obese women. Int J Obes Relat Metab Disord 2004; 28: 993-997.
24.
Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-334.
25.
Ogata A, Morishima A, Hirano T, et al. Improvement of HbA1c during treatment with humanized anti-interleukin 6 receptor antibody, tocilizumab. Ann Rheum Dis 2011; 70: 1164-1165.
26.
Yamaguchi K, Itoh Y, Yokomizo C, et al. Blockade of interleukin-6 signaling enhances hepatic steatosis but improves liver injury in methionine choline-deficient diet-fed mice. Lab Invest 2010; 90: 1169-1178.
27.
Toussirot E, Grandclément E, Gaugler B, et al. Serum adipokines and adipose tissue distribution in rheumatoid arthritis and ankylosing spondylitis. A comparative study. Front Immunol 2013; 4: 453.
28.
Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998; 83: 847-850.
29.
Ruge T, Lockton JA, Renstrom F, et al. Acute hyperinsulinemia raises plasma interleukin-6 in both nondiabetic and type 2 diabetes mellitus subjects, and this effect is inversely associated with body mass index. Metabolism 2009; 58: 860-866.
30.
Wang P, Mariman E, Renes J, Keijer J. The secretory function of adipocytes in the physiology of white adipose tissue. J Cell Physiol 2018; 216: 3-13.
31.
Mangge H, Summers KL, Meinitzer A, et al. Obesity-related dysregulation of the tryptophan-kynurenine metabolism: role of age and parameters of the metabolic syndrome. Obesity [Silver Spring] 2014; 22: 195-201.
32.
Yamashita M, Yamamoto T. Tryptophan and kynurenic Acid may produce an amplified effect in central fatigue induced by chronic sleep disorder. Int J Tryptophan Res 2014; 7: 9-14.
33.
Capuron L, Schroecksnadel S, Feart C, et al. Chronic low-grade inflammation in elderly persons is associated with altered tryptophan and tyrosine metabolism: role in neuropsychiatric symptoms. Biol Psychiatry 2011; 70: 175-182.
34.
Dekker MJ, Lee S, Hudson R, et al. An exercise intervention without weight loss decreases circulating interleukin-6 in lean and obese men with and without type 2 diabetes mellitus. Metabolism 2007; 56: 332-338.
35.
Messier SP, Mihalko SL, Legault C, et al. Effects of intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes among overweight and obese adults with knee osteoarthritis: the IDEA randomized clinical trial. JAMA 2013; 310: 1263-1273.
36.
Gusba JE, Wilson RJ, Robinson DL, Graham TE. Interleukin-6 and its mRNA responses in exercise and recovery: relationship to muscle glycogen. Scand J Med Sci Sports 2008; 18: 77-85.
37.
Payette C, Blackbur P, Lamarche B, et al. Sex differences in postprandial plasma tumor necrosis factor-alpha, interleukin-6, and C-reactive protein concentrations. Metabolism 2009; 58: 1593-1601.
38.
Arakawa M, Ebato C, Mita T, et al. Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects. Metabolism 2008; 57: 1299-1306.
39.
Robinson LE, Buchholz AC, Mazurak VC. Inflammation, obesity, and fatty acid metabolism: influence of n-3 polyunsaturated fatty acids on factors contributing to metabolic syndrome. Appl Physiol Nutr Metab 2007; 32: 1008-1024.
40.
Rossi A, Kapahi P, Natoli G, et al. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of I ĸappa B kinase. Nature 2000; 403: 103-108.
41.
Mori TA, Woodman RJ. The independent effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors in humans. Curr Opin Clin Nutr Metab Care 2006; 9: 95-104.
42.
Schmitz G, Ecker J. The opposing effects of n-3 and n-6 fatty acids. Prog Lipid Res 47: 147-155.
43.
Calder PC. n23 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 2008; 83: S1505-1519.
44.
Middleton EJ, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease and cancer. Pharmacol Rev 2000; 52: 673-651.
45.
Kempuraj D, Madhappan B, Christodoulou S, et al. Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells. Br J Pharmacol 2005; 145: 934-944.
46.
Park HH, Lee S, Son HY, et al. Flavonoids inhibit histamine release and expression of proinflammatory cytokines in mast cells. Arch Pharm Res 2008; 31: 1303-1311.
47.
Bae SC, Jung WJ, Lee EJ, et al. Effects of antioxidant supplements intervention on the level of plasma inflammatory molecules and disease severity of rheumatoid arthritis patients. J Am Coll Nutr 2009; 28: 56-62.
48.
Shin HY, Kim SH, Jeong HJ, et al. Epigallocatechin-3-gallate inhibits secretion of TNF-αlpha, IL-6 and IL-8 through the attenuation of ERK and NF-ĸappa B in HMC-1 cells. Int Arch Allergy Immunol 2007; 142: 335-344.
49.
Jang S, Kelley KW, Johnson RW. Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1. Proc Natl Acad Sci U S A 2008; 105: 7534-7539.
50.
Vaghef-Mehrabany E, Alipour B, Homayouni-Rad A, et al. Probiotic supplementation improves inflammatory status in patients with rheumatoid arthritis. Nutrition 2014; 30: 430-435.
51.
Villalvilla A, da Silva JA, Largo R, et al. 6-Shogaol inhibits chondrocytes’ innate immune responses and cathepsin-K activity. Mol Nutr Food Res 2014; 58: 256-266.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
